- Home
- CXAI vs APM Comparison
CXAI vs APM Comparison
Compare CXAI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXAI | APM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CXAI | APM |
|---|---|---|
| Price | $0.26 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.0M | 35.5K |
| Earning Date | 04-06-2026 | 10-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.65 |
| 52 Week High | $1.49 | $4.47 |
Technical Indicators
Market Signals| Indicator | CXAI | APM |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 60.76 |
| Support Level | $0.24 | $0.86 |
| Resistance Level | $0.38 | $1.11 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 62.38 | 82.77 |
Price Performance
Historical ComparisonAbout CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.